SHOCKING: Sage rapeutics - What They Never Told You

8 Analysts Have This to Say About Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Benzinga · May 24, 2022

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Benzinga · May 13, 2022

Analyst Ratings for Sage Therapeutics

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 4, 2022